# TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT

> **NCT03741244** · PHASE2 · UNKNOWN · sponsor: **The Second Hospital of Hebei Medical University** · enrollment: 211 (estimated)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** apatinib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03741244
- **Lead sponsor:** The Second Hospital of Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-06
- **Primary completion:** 2022-10
- **Final completion:** 2023-02
- **Target enrollment:** 211 (ESTIMATED)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03741244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03741244, "TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03741244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*